Lung fibrosis in COVID-19 survivors: histone deacetylase inhibitors as a promising therapeutic strategy
- 作者: Aitbaev K.A1, Murkamilov I.T2,3, Murkamilova H.A4, Fomin V.V5, Kudaibergenova I.O2, Yusupov F.A6
-
隶属关系:
- Research Institute of Molecular Biology and Medicine
- Kyrgyz State Medical Academy named after I.K. Akhunbaev
- Kyrgyz-Russian Slavic University
- SEI HPE Kyrgyz-Russian Slavic University
- I.M. Sechenov First Moscow State Medical University (Sechenov University) of the Ministry of Healthcare of Russia
- Osh State University
- 期: 卷 24, 编号 8 (2021)
- 页面: 3-12
- 栏目: Articles
- URL: https://journals.eco-vector.com/1560-9596/article/view/112871
- DOI: https://doi.org/10.29296/25877313-2021-08-01
- ID: 112871
如何引用文章
详细
全文:
作者简介
K. Aitbaev
Research Institute of Molecular Biology and Medicine
Email: kaitbaev@yahoo.com
Dr.Sc. (Med.), Professor, Head of the Department of Head. Laboratory of Pathological Physiology, Board Member of Chronic Kidney Disease Specialists Society of Kyrgyzstan
I. Murkamilov
Kyrgyz State Medical Academy named after I.K. Akhunbaev; Kyrgyz-Russian Slavic University
Email: murkamilov.i@mail.ru
Ph.D. (Med.), Acting Associate Professor of the Department of Faculty Therapy; Senior Lecturer, Nephrologist, Chairman of the Board of Chronic Kidney Disease Specialists Society of Kyrgyzstan
H. Murkamilova
SEI HPE Kyrgyz-Russian Slavic University
Email: murkamilovazh.t@mail.ru
Post-graduate Student, the Department of Therapy № 2
V. Fomin
I.M. Sechenov First Moscow State Medical University (Sechenov University) of the Ministry of Healthcare of Russia
Email: fomin@mma.ru
Dr.Sc. (Med.), Professor, Corresponding Member of RAS, Head of the Department of Faculty Therapy № 1, Sklifosovsky Institute; Vice-rector in Clinical Work and Continuous Professional Education
I. Kudaibergenova
Kyrgyz State Medical Academy named after I.K. Akhunbaev
Email: k_i_o2403@mail.ru
Dr.Sc. (Med.), Professor, Rector
F. Yusupov
Osh State UniversityDr.Sc. (Med.), Professor, Head of the Department Neurology, Psychiatry and Neurosurgery of Medicinal Faculty, Board Member of Chronic Kidney Disease Specialists Society of Kyrgyzstan; Chief Neurologist of Southern Region of Kyrgyzstan
参考
- Wang H., Li X., Li T., et al. The genetic sequence, origin, and diagnosis of SARS- CoV-2. Eur. J. Clin. Microbiol. Infect. Dis. Off Publ. Eur. Soc. Clin. Microbiol. 2020; https://doi.org/10.1007/s10096-020-03899-4
- CDC, Coronavirus disease 2019 (COVID-19), in: Cent. Dis. Control Prev, 2020. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/evidence-table.html. (Accessed 25 July 2020).
- Gu J., Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. Am. J. Pathol 2007; 170:11361147. https://doi.org/10.2353/ajpath.2007.061088
- Zhang P., Li J., Liu H., et al. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study. Bone Res. 2020; 8: 8. https://doi.org/10.1038/s41413-020-0084-5
- Tse G.M., To K.F., Chan P.K., et al. Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS). J. Clin. Pathol. 2004; 57: 260-265. https://doi.org/10.1136/jcp.2003.013276
- Antonio G.E., Wong K.T., Hui D.S., et al. Thin-section CT in patients with severe acute respiratory syndrome following hospital discharge: preliminary experience. Radiology. 2003; 228: 810-815. https://doi.org/10.1148/radiol.2283030726
- Wong K.T., Antonio G.E., Hui D.S., et al. Severe acute respiratory syndrome: thin- section computed tomography features, temporal changes, and clinicoradiologic correlation during the convalescent period. J. Comput. Assist. Tomogr. 2004; 28: 790-795. https://doi.org/10.1097/00004728-200411000-00010
- Wu X., Dong D., Ma D. Thin-section computed tomography manifestations during convalescence and long-term follow-up of patients with severe acute respiratory syndrome (SARS). Med. Sci. Monit. Int. Med. J. Exp.Clin. Res. 2016; 22: 27932799. https://doi.org/10.12659/msm.896985
- Muller N.L., Ooi G.C., Khong P.L., et al. High-resolution CT findings of severe acute respiratory syndrome at presentation and after admission. AJR Am. J. Roentgenol. 2004; 182: 39-44. https://doi.org/10.2214/ajr.182.1.1820039
- Chu W.C., Li A.M., Ng A.W., et al. Thin-section CT 12 months after the diagnosis of severe acute respiratory syndrome in pediatric patients. AJR Am. J. Roentgenol. 2006; 186: 1707-1714. https://doi.org/10.2214/AJR.05.0382
- Das K.M., Lee E.Y., Singh R., et al. Follow-up chest radiographic findings in patients with MERS-CoV after recovery. Indian J. Radiol. Imaging. 2017; 27: 342-349. https://doi.org/10.4103/ijri.IJRI_469_16
- Mossel E.C., Wang J., Jeffers S., et al. SARS-CoV replicates in primary human alveolar type II cell cultures but not in type I-like cells. Virology. 2008; 372: 127-135. https://doi.org/10.1016/j.virol.2007.09.045
- Weinheimer V.K., Becher A., Tonnies M., et al. Influenza A viruses target type II pneumocytes in the human lung. J. Infect. Dis. 2012; 206: 1685-1694. https://doi.org/10.1093/infdis/jis455
- Delpino M.V., Quarleri J. SARS-CoV-2 pathogenesis: imbalance in the renin- angiotensin system favors lung fibrosis. Front. Cell. Infect. Microbiol. 2020; 10: 340. https://doi.org/10.3389/fcimb.2020.00340
- Коган Е.А., Березовский Ю.С., Проценко Д.Д. и др. Патологическая анатомия инфекции, вызванной SARS-CoV-2. Судебная медицина. 2020; 6(2): 8-30. https://doi.org/10.19048/2411-8729-2020-6-2-8-30
- Ni W., Yang X., Yang D., et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care Lond Engl. 2020; 24: 422. https://doi.org/10.1186/s13054-020-03120-0
- Leng L., Cao R., Ma J., et al. Pathological features of COVID-19-associated lung injury: a preliminary proteomics report based on clinical samples. Signal Transduct Target Ther. 2020; 5: 240. https://doi.org/10.1038/s41392-020-00355-9
- Meyer K.C. Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis. Expert Rev Respir Med. 2017; 11: 343-359. https://doi.org/10.1080/17476348.2017.1312346
- Richeldi L., Collard H.R., Jones M.J. Idiopathic pulmonary fibrosis. Lancet Lond Engl. 2017 389: 1941-1952. https://doi.org/10.1016/S0140-6736(17)30866-8
- Vall'ee A., Lecarpentier Y. TGF-Р in fibrosis by acting as a conductor for contractile properties of myofibroblasts. Cell Biosci. 2019; 9: 98. https://doi.org/10.1186/s13578-019-0362-3
- Wynn T.A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008;214:199-210. https://doi.org/10.1002/path.2277
- Pardo A., Cabrera S., Maldonado M., Selman M. Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis. Respir. Res. 2016; 17: 23. https://doi.org/10.1186/s12931-016-0343-6
- George P.M., Wells A.U., Jenkins R.G. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir. Med. 2020; https://doi.org/10.1016/S2213-2600(20)30225-3
- LeaskA. COVID-19: is fibrosis the killer? J. Cell. Commun. Signal. 2020; 14: 255. https://doi.org/10.1007/s12079-020-00569-0
- Wu C., Chen X., Cai Y., et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. 2020; https://doi.org/10.1001/jamainternmed.2020.0994
- Yu M., Liu Y., Xu D., et al. Prediction of the development of pulmonary fibrosis using serial thin-section CT and clinical features in patients discharged after treatment for COVID-19 pneumonia. Korean J. Radiol. 2020; 21: 746-755. https://doi.org/10.3348/kjr.2020.0215
- MGH FLARE. June 2 - will COVID-19 cause more IPF? https://us19.campaignarchive.com/?u=ef98149bee3f299584374540a&id=737fad9de0. (Accessed 28 November 2020).
- Ojo A.S., Balogun S.A., Williams O.T., Ojo O.S. Pulmonary fibrosis in COVID-19 survivors: predictive factors and risk reduction strategies. Pulm Med. 2020;2020:6175964. https://doi.org/10.1155/2020/6175964
- Wigen J., Lofdahl A., Bjermer L., et al. Converging pathways in pulmonary fibrosis and Covid-19 - the fibrotic link to disease severity. Respir Med X. 2 2020; 100023. https://doi.org/10.1016/j.yrmex.2020.100023
- Kobayashi T., Tanaka K., Fujita T., et al. Bidirectional role of IL-6 signal in pathogenesis of lung fibrosis. Respir. Res. 2015; 16: 99. https://doi.org/10.1186/s12931-015-0261-z
- Пустоветова М.Г., Чикинев Ю.А., Пионтковская К.А. Молекулярно-клеточные механизмы развития фиброза легких и спонтанного пневмоторакса. Бюллетень СО РАМН. 2014; 34(5): 17-21
- Minshall E.M., Leung D.Y., Martin R.J., et al. Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma. Am. J. Respir. Cell Mol. Biol. 1997; 17: 326-333. https://doi.org/10.1165/ajrcmb.17.3.2733
- Khalil N., O’Connor R.N., Flanders K.C., et al. TGF-beta 1, but not TGF-beta 2 or TGF-beta 3, is differentially present in epithelial cells of advanced pulmonary fibrosis: an immunohis-tochemical study. Am. J. Respir. Cell Mol. Biol. 1996; 14:131138. https://doi.org/10.1165/ajrcmb.14.2.8630262
- Khalil N., Parekh T. V., O ’Connor R., et al. Regulation of the effects of TGF-beta 1 by activation of latent TGF-beta 1 and differential expression of TGF-beta receptors (T beta R-I and T beta R-II) in idiopathic pulmonary fibrosis. Thorax. 2001; 56:907-915. https://doi.org/10.1136/thorax.56.12.907
- Roberts A.B., Piek E., Bottinger E.P., et al. Is Smad3 a major player in signal transduction pathways leading to fibrogenesis? Chest. 2001; 120: 43S-47S. https://doi.10.1378/chest.120.1_suppl.s43-a
- Leask A., Abraham D.J. TGF-beta signaling and the fibrotic response. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2004; 18:816-827. https://doi.org/10.1096/fj.03-1273rev
- Kandasamy M., Lehner B., Kraus S., et al. TGF-beta signalling in the adult neurogenic niche promotes stem cell quiescence as well as generation of new neurons. J. Cell. Mol. Med. 2014; 18: 1444-1459. https://doi.org/10.1111/jcmm.12298
- Venkataraman T., Frieman M.B. The role of epidermal growth factor receptor (EGFR) signaling in SARS corona-virus-induced pulmonary fibrosis. Antivir. Res. 2017; 143: 142-150. https://doi.org/10.1016/j.antiviral.2017.03.022
- Watanabe-Takano H., Takano K., Hatano M., et al. DA-Raf-mediated suppression of the Ras-ERK pathway is essential for TGF-P1-induced epithelial-mesenchymal transition in alveolar epithelial type 2 cells. PLoS One. 2015; 10:e0127888. https://doi.org/10.1371/journal.pone.0127888
- Zhao X., Nicholls J.M., Chen Y.G. Severe acute respiratory syndrome-associated coronavirus nucleocapsid protein interacts with Smad3 and modulates transforming growth factor-beta signaling. J. Biol. Chem. 2008; 283: 3272-3280. https://doi.org/10.1074/jbc.M708033200
- Allen J.T., Knight R.A., Bloor C.A., et al. Enhanced insulinlike growth factor binding protein-related protein 2 (connective tissue growth factor) expression in patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am. J. Respir. Cell Mol. Biol. 1999; 21: 693-700. https://doi.org/10.1165/ajrcmb.21.6.3719
- Torr E.E., Ngam C.R., Bernau K., et al. Myofibroblasts exhibit enhanced fibronectin assembly that is intrinsic to their contractile phenotype. J. Biol. Chem. 2015; 290: 6951-6961. https://doi.org/10.1074/jbc.M114.606186
- Desmouli'ere A., Geinoz A., Gabbiani F., et al. Transforming growth factor-beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J. Cell Biol. 1993; 122: 103-111. https://doi.org/10.1083/jcb.122.1.103
- Rajasekaran S., Vaz M., Reddy S.P. Fra-1/AP-1 transcription factor negatively regulates pulmonary fibrosis in vivo. PLoS One. 2012; 7:e41611. https://doi.org/10.1371/journal.pone.0041611
- Shi K., Jiang J., Ma T., et al. Pathogenesis pathways of idiopathic pulmonary fibrosis in bleomycin-induced lung injury model in mice. Respir. Physiol. Neurobiol. 2014; 190: 113117. https://doi.org/10.1016/j.resp.2013.09.011
- Pattarayan D., Rajarajan D., Ayyanar S., et al. C-phycocyanin suppresses transforming growth factor-P1-induced epithelial mesenchymal transition in human epithelial cells. Pharmacol Rep PR. 2017; 69: 426-431. https://doi.org/10.1016/j.pharep.2016.12.013
- Pattarayan D., Thimmulappa R.K., Ravikumar V., Rajasekaran S. Diagnostic potential of extracellular microRNA in respiratory diseases. Clin. Rev. Allergy Immunol. 2018; 54: 480-492. https://doi.org/10.1007/s12016-016-8589-9
- Rajasekaran S., Rajaguru P., Sudhakar Gandhi P.S. MicroRNAs as potential targets for progressive pulmonary fibrosis. Front. Pharmacol. 2015; 6: 254. https://doi.org/10.3389/fphar.2015.00254
- Myllarniemi M., Kaarteenaho R. Pharmacological treatment of idiopathic pulmonary fibrosis - preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine. EurClinRespir J. 2015; 2. https://doi.org/10.3402/ecrj.v2.26385
- Margaritopoulos G.A., Vasarmidi E., Antoniou K.M. Pirfeni-done in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy. Core Evid 2016; 11: 11-22. https://doi.org/10.2147/CE.S76549
- Kato M., Sasaki S., Nakamura T., et al. Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis. Sci. Rep. 2019; 9: 12062. https://doi.org/10.1038/s41598-019-48593-4
- Zhang H. A Randomized Open-label Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Severe and Critical Novel Coronavirus Infection. dinic. altrials. Gov. 2020.
- Pleasants R., Tighe R.M. Management of idiopathic pulmonary fibrosis. Ann. Pharmacother. 2019; 53: 1238-1248. https://doi.org/10.1177/1060028019862497
- Tang J., Yan H., Zhuang S. Histone deacetylases as targets for treatment of multiple diseases. Clin. Sci (Lond.). 2013 jun; 124(11): 651-662. https://doi.org/1042/CS20120504
- Glenisson W., Castronovo V., Waltregny D. Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic differentiation. Biochim. Biophys. Acta. 2007; 1773: 15721582. https://doi.org/10.1016/j.bbamcr.2007.05.016
- Guo W., Shan B., Klingsberg R.C., et al. Abrogation of TGF-beta1-induced fibroblast-myofibroblast differentiation by his-tone deacetylase inhibition. Am. J. Physiol. Lung. Cell. Mol. Physiol. 2009; 297: L864-L870. https://doi.org/10.1152/aj-plung.00128.2009
- Korfei M., Skwarna S., Henneke I., et al. Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis. Thorax. 2015; 70: 1022-1032. https://doi.org/10.1136/thoraxjnl-2014-206411
- Barter M.J., Pybus L., Litherland G.J., et al. HDAC-mediated control of ERK- and PI3K-dependent TGF-P-induced extracellular matrix-regulating genes. Matrix. Biol. J. Int. Soc. MatrixKi Biol. 2010; 29: 602-612. https://doi.org/10.1016/j.matbio.2010.05.002
- Jones D.L., Haak A.J., Caporarello N., et al. TGFP-induced fibroblast activation requires persistent and targeted HDAC-mediated gene repression. J. Cell Sci. 2019; 132. https://doi.org/10.1242/jcs.233486
- Saito S., Zhuang Y., Suzuki T., et al. HDAC8 inhibition ameliorates pulmonary fibrosis. Am. J. Physiol. Lung. Cell. Mol. Physiol. 2019; 316: L175-L186. https://doi.org/10.1152/ajplung.00551.2017
- Yoon S., Kang G., Eom G.H. HDAC inhibitors: therapeutic potential in fibrosis-associated human diseases. Int. J. Mol. Sci. 2019; 20. https://doi.org/10.3390/ijms20061329
- Coward W.R., Watts K., Feghali-Bostwick C.A., et al. Defective histone acetylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis. Mol. Cell. Biol. 2009; 29: 4325-4339. https://doi.org/10.1128/MCB.01776-08
- Huang S.K., Scruggs A.M., Donaghy J., et al. Histone modifications are responsible for decreased Fas expression and apoptosis resistance in fibrotic lung fibroblasts. Cell. Death Dis. 2013;4:e621. https://doi.org/10.1038/cddis.2013.146
- Saito S., Zhuang Y., Shan B., et al. Tubastatin ameliorates pulmonary fibrosis by targeting the TGFP-PI3K-Akt path way. PLoS One. 2017; 12:e0186615. https://doi.org/10.1371/journal.pone.0186615
- Korfei M., Stelmaszek D., MacKenzie B., et al. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibi-tor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis. PLoS One. 2018; 13:e0207915. https://doi.org/10.1371/journal.pone.0207915